TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06308237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RESISTED EXERCISES
Description: Patients will perform Chest plank for 30 seconds with 4 repetitions.~Then the Participants will perform these exercises for 1 minute each with 4 repetitions:~Wide grip lateral pull down , Lying triceps press, Sit up squats, Barbell curl each.~And will perform Thigh adduction for1 minute with 2 repititions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BALANCE EXERCISES
Description: Static and dynamic balance exercises will include:~Patients will perform Arm abduction holding a half-kg dumbbell, Opposite arm and leg in a quadruped position, Walking in a tandem stance(forward and backward), Turning and bending to the sides in a standing position, Pass through obstacles in a spiral, for 2 minutes each.~Then they will perform throwing a medicine ball to investigator and back while trying to maintain balance, Tandem stance, Walking backwards, Two-leg bridge as well as single (2 repetitions), Leg bridge (raising the other leg), walking on the heel, performing rhythmic movements while stepping on a circular environment and balance board exercises, for 1 minute each.~And will Walk up and down the stairs for 3 minutes.
Study: NCT06395935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wecare (website)
Description: support feedback of qutionaire \& supply educational contents
Study: NCT04393896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeChat-based integrative family intervention (WIFI)
Description: The WIFI program will include three key components: psycho-education through WeChat Official Account publications, peer-support through a WeChat chat group, and professional support through WeChat private chat and video call
Study: NCT06083571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Non-inferiority

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Non-inferiority

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Description: Adjunct

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochlorperazine
Description: Adjunct

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Adjunct

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Adjunct
Study: NCT06575868

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myo-inositol
Description: Patients would begin taking myoinositol upon recruitment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Myo-inositol placebo
Description: Patients would begin taking placebo upon recruitment
Study: NCT06641518

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: a therapeutic modality employing electric current to relieve pain by activating peripheral nerves. The evolution of TENS units alongside technological advancements has led to user-friendly interfaces and enhanced portability, with units now small enough to be carried in a pocket.
Study: NCT05821205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Persuasion
Description: Narratives will use anonymous testimonials from our prior work combined with open-source pictures. The researchers will ask participants to rate the testimonial message as a measure of engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocity
Description: Researchers will track clicking on the gift card as a measure of engagement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Feedback
Description: Researchers will track clicking on a link and/or opening to review visual data as a source of engagement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment
Description: Providers will receive a commitment message and be asked to reply as a measure of engagement.
Study: NCT06277219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT010
Description: LAT010 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT010
Description: LAT010 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT010 + ICI
Description: LAT010 combination with PD-1 inhibitor
Study: NCT05834738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan
Description: Period A (12 Weeks) - Film-coated tablet, Washout Period: 12 weeks, Period B (24 Weeks) - Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrasentan
Description: Period B (12 Weeks) - Placebo, Washout Period: 12 weeks, Period A (24 Weeks) - Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06465875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading a book
Description: Individuals in the intervention group will be read a storybook for three nights.
Study: NCT06427044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anterior serratus block group
Description: Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a single anterior serranus plane block
Study: NCT05757726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velocity pAVF system
Description: A second generation percutaneous AVF device that creates an AVF between the proximal radial artery and cubital perforating vein.
Study: NCT05973045

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Hysteroscopy 24 Centigrade Degree
Description: Operative hysteroscopy will be performed at room temperature distention medium.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Hysteroscopy 37 Centigrade Degree
Description: Operative hysteroscopy will be performed using a heated distention medium.
Study: NCT04868357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Two 45-minute group sessions in which patients experience hypnosis and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. First session is introductory. Second session addresses concerns that patients may have identified after using self-hypnosis. Both sessions include group hypnosis exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, eye closure, relaxation, nodding). Patients are asked to concentrate in nature-themed metaphors and hypnotic suggestions of pure air entering their lungs. Both sessions end with a round of questions, instructions and motivation to use self-hypnosis throughout the duration of the PRP and beyond.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: Two 45-minute group sessions in which patients experience dynamic relaxation and learn how to use it for the self-management of anxiety and anxiety-related dyspnea. Both sessions include group relaxation exercises. Both sessions are to be administered in an identical manner, and require the same motor and communication responses from the patient (i.e., concentrate on the practitioner's voice, stretching, breathing exercises, nodding). Both sessions end with a round of questions, instructions and motivation to use relaxation throughout the duration of the PRP and beyond.
Study: NCT04767087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Honey
Description: 0.5 gm/Kg/day honey

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nigella sativa seed
Description: 40 mg/Kg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty capsule with sugar water
Study: NCT04984187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity laser plus exercise
Description: high intensity laser plus exercise

Intervention type: DEVICE
Group type: OTHER
Intervention: high intensity laser only
Description: high intensity laser only

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: exercise only
Study: NCT06222229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: All patients included in the study, both in the non-bandaging group and in the bandaging group, will receive a series of general measures as a recommendation, consisting of the following:~* Administration of anti-inflammatory drugs as ibuprofen at 7.5 mg/kg/8 hours for 2-3 days. If pain continues, recommendation of paracetamol 15 mg/kg 4 hours after ibuprofen.~* Application of local ice for a maximum of 10 minutes as required.~* Elevation of the affected limb when resting.~* Early mobilization and load according to tolerance, using crutches if required.~* Sports rest at least for one week or until the patient is able to walk without pain, with gradual incorporation according to tolerance. During the following year, use of elastic ankle brace for sports activities.~The control group will not receive any special intervention.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functional bandage
Description: The functional bandage will consist of a standardized wrapping in several phases. First, with 6 mm silk tape, open anchors were placed in the distal region of the metatarsals of the foot and in the middle third of the affected leg. Next, a strip of tape was applied in stirrup fashion, starting from the proximal anchor and exerting pressure cranially on the side of the affected ligament. This support was interspersed three times with another strip of tape, starting from the foot anchor and wrapping behind the ankle. Once complete, it was covered with a 7.5 cm Tensoplast spiral bandage, taking care to apply gentle pressure. The emergency nurses underwent dual training, consisting of an instructional video and a half-hour practical session. Reminder posters were also displayed in the technique box where such procedures are typically performed.~As the control group, general measures will be recommended
Study: NCT04629339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB086550
Description: INCB086550 will be administered orally twice a day.
Study: NCT06503887

Intervention type: OTHER
Intervention: Stool sample collection
Description: Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis

Intervention type: OTHER
Intervention: Stool sample collection
Description: Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis

Intervention type: OTHER
Intervention: Stool sample collection
Description: Following the approval of the legal guardians, a stool collection container was given to the parents in order to collect the stools. Stools were kept at 4ºC for 24h max, then transported to the laboratory, aliquoted and stored at -80ºC for further analysis
Study: NCT06679166

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05376462

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantra System with the QStat Cartridge
Description: Whole blood viscoelastic test system that provides an assessment of the patient's coagulation status.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laboratory Tests
Description: Laboratory tests that provide information about a patient's coagulation status.
Study: NCT06452238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External Oblique Intercostal Plane Block
Description: Patients will receive external oblique intercostal plane block .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: Patients will receive ultrasound-guided transversus abdominis plane block.
Study: NCT04635189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16 milligrams/kilograms intravenously weekly for 8 treatments, followed by every 2 weeks for 8 treatments, followed by every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 milligrams by mouth daily days 1-21 out of a 28 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 20 milligrams by mouth or intravenously at least 60 minutes prior to first infusion of daratumumab
Study: NCT05061706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42 mg capsules administered orally, once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally, once daily.
Study: NCT05295056

Intervention type: DEVICE
Intervention: AFGen1 Device Wear Test
Description: Participant wears the device for 7 days

Intervention type: DEVICE
Intervention: AFGen1 Device Wear Test
Description: Participant wears the device for 7 days

Intervention type: DEVICE
Intervention: AFGen 1 Device Single Use
Description: Participant wears the device in conjunction with a standard ECG
Study: NCT04940767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Isotretinoin is a retinoic acid analogue (13-cis-retinoic acid) supplied as oral capsules. and was approved in the US for the treatment of severe acne vulgaris in 1982 under the brand name Accutane®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amzeeq 4% Topical Foam
Description: AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amzeeq 4% Topical Foam
Description: AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
Study: NCT06556290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten free and casein free diet
Description: Parents will be advised for three months to ensure that children with autism spectrum disorder follow a casein-free and gluten-free diet during this period.
Study: NCT05754463

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The effect of plyometric training on balance and proprioception in athletes in different branches
Description: Investigating the effect of plyometric training on balance and proprioception in athletes in different branches

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The effect of plyometric training on balance and proprioception in athletes in different branches
Description: Investigating the effect of plyometric training on balance and proprioception in athletes in different branches
Study: NCT06253845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CG0070
Description: CG0070 will be administered at a dose of 1x10\^12 vp intravesically following a sequence of bladder washes with DDM and normal saline.
Study: NCT05970640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3006337
Description: BI 3006337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3006337
Description: BI 3006337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3006337
Description: BI 3006337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3006337
Description: BI 3006337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 3006337
Description: Placebo matching BI 3006337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 3006337
Description: Placebo matching BI 3006337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BI 3006337
Description: Placebo matching BI 3006337
Study: NCT05703841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.
Study: NCT03304717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF) and Emtricitabine (FTC)
Description: Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF) and Emtricitabine (FTC)
Description: Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Tenofovir and Placebo for Emtricitabine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Tenofovir and Placebo for Emtricitabine
Study: NCT05470686

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood gas via arterial catheter
Description: Patients will have a blood sample plus a lung ultrasound before and after the physical therapy session combined with non invasive ventilation the morning after the heart surgery
Study: NCT05382130

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Test all
Description: In the test all arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results.